SEC Form 4 · accession 0001209191-17-027183
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Farah Champsi
Director
Period of report
Apr 13, 2017
Accepted (ET)
Apr 17, 2017 · 9:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Apr 13, 2017 | S | 72,275 | $82.39 | D | 191,144 | I | See Footnote |
| Common StockF4,F3 | Apr 17, 2017 | S | 43,001 | $82.48 | D | 148,143 | I | See Footnote |
| Common StockF3 | Apr 17, 2017 | S | 100 | $83.06 | D | 148,043 | I | See Footnote |
| Common StockF5 | holding | — | — | — | 79,152 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 1,500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on October 19, 2016. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.
- F3The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5Includes 58,998 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain RSUs in her capacity as a director of the Company, and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs.